B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
KYTX
Kyverna TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Kyverna has a concrete regulatory path for miv-cel in SPS, three RMAT indications, upcoming Q3 data, and reported $199.4 million of cash, cash equivalents, and marketable securities with operating runway into 2028 [#SEC-8K-2026-08-11]. Secondary analyst pages show recent Buy reiterations with targets of $25-$33, including Wells Fargo at $33 and Morgan Stanley at $33 [StockAnalysis](https://stockanalysis.com/stocks/kytx/forecast/).
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.1.
What can break
KYSA-8 and KYSA-6 outcomes remain exposed to efficacy durability, safety, tolerability, enrollment, and manufacturing execution risk.
Momentum
42
Value
41
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $18.00 · Bear $4.50Analysis 2026-08-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $30.40
Why
Momentum42 · Δ7d -0.8
Value41 · Δ7d 0.0
Sentiment82 · Δ7d +11.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +11.1.
Contradictions & invalidation
- • KYSA-8 and KYSA-6 outcomes remain exposed to efficacy durability, safety, tolerability, enrollment, and manufacturing execution risk.
- • Post-print price action was mixed rather than clearly confirmatory: FinanceCharts shows +1.65% on August 11, +0.37% on August 12, +9.55% on August 17, and -5.03% on August 18 [FinanceCharts](https://www.financecharts.com/stocks/KYTX/summary/price).
- • The thesis remains binary: delayed BLA completion, weaker-than-expected durability or tolerability, slower gMG enrollment, or higher-than-planned spending could overwhelm the stated runway and pressure the stock.
Catalyst clock
2026-09-30
Q3 miv-cel clinical data updates
Lead driver: Sentiment · See AI snapshot
Momentum
42
9% active weight
Current posture
7d trendImproving
Δ7d
-0.8
Δ21d
+17.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
82
62% active weight
Current posture
7d trendImproving
Δ7d
+11.1
Δ21d
-15.1
Why this grade
Composite grade B. Momentum 41.7 / Value 41.2 / Sentiment 81.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$553.5M
Beta
-
Shares Out
61.84M
P/E (TTM) · Derived
-2.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.90
Rev YoY
-100.0%
EPS YoY
-35.4%
Gross Margin
-474.1%
Op Margin
-
Net Debt
-$250.22M
Current Ratio
9.06
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data